APA (7th ed.) Citation

D, T., D, P., P, S., P, S., K, W., SY, S., . . . M, A. (2025). Hepatic sinusoidal congestion associated with inotuzumab therapy in patients with B-cell acute lymphoblastic leukemia, a proposal for a new clinical entity: Calicheamicin syndrome. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 31(4), 656. https://doi.org/10.1177/10781552251332278

Chicago Style (17th ed.) Citation

D, Tai, Park D, Soria P, Shah P, Wick K, Son SY, Jeon WJ, Lee KJ, and Akhtari M. "Hepatic Sinusoidal Congestion Associated with Inotuzumab Therapy in Patients with B-cell Acute Lymphoblastic Leukemia, a Proposal for a New Clinical Entity: Calicheamicin Syndrome." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 31, no. 4 (2025): 656. https://doi.org/10.1177/10781552251332278.

MLA (9th ed.) Citation

D, Tai, et al. "Hepatic Sinusoidal Congestion Associated with Inotuzumab Therapy in Patients with B-cell Acute Lymphoblastic Leukemia, a Proposal for a New Clinical Entity: Calicheamicin Syndrome." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 31, no. 4, 2025, p. 656, https://doi.org/10.1177/10781552251332278.